157 related articles for article (PubMed ID: 24103580)
41. Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse.
Qi JN; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1990 Aug; 254(2):683-9. PubMed ID: 2166801
[TBL] [Abstract][Full Text] [Related]
42. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
43. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
44. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
45. Nalbuphine.
Schmidt WK; Tam SW; Shotzberger GS; Smith DH; Clark R; Vernier VG
Drug Alcohol Depend; 1985 Feb; 14(3-4):339-62. PubMed ID: 2986929
[TBL] [Abstract][Full Text] [Related]
46. Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.
Stavitskaya L; Coop A
Mini Rev Med Chem; 2011 Oct; 11(12):1002-8. PubMed ID: 21861811
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5alpha-epoxy-6,7:4',5'-pyrimidin omorphinans.
Xu W; Huang LF; Bauer L; Bhargava HN; Dunn WJ
Bioorg Med Chem Lett; 1999 Dec; 9(23):3375-80. PubMed ID: 10612602
[TBL] [Abstract][Full Text] [Related]
48. Differentiation of multiple analgesic opiate receptors.
Fürst S; Knoll J
Int J Tissue React; 1985; 7(1):69-77. PubMed ID: 2861170
[TBL] [Abstract][Full Text] [Related]
49. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
50. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine.
Calcagnetti DJ; Holtzman SG
Pharmacol Biochem Behav; 1991 Jan; 38(1):185-90. PubMed ID: 2017444
[TBL] [Abstract][Full Text] [Related]
51. Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice.
SUN JF; WANG YH; LI FY; LU G; TAO YM; CHENG Y; CHEN J; XU XJ; CHI ZQ; NEUMEYER JL; ZHANG A; LIU JG
Acta Pharmacol Sin; 2010 Dec; 31(12):1547-52. PubMed ID: 21102484
[TBL] [Abstract][Full Text] [Related]
52. 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile.
King MA; Su W; Nielan CL; Chang AH; Schütz J; Schmidhammer H; Pasternak GW
Eur J Pharmacol; 2003 Jan; 459(2-3):203-9. PubMed ID: 12524147
[TBL] [Abstract][Full Text] [Related]
53. Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats.
Leventhal L; Silva RM; Rossi GC; Pasternak GW; Bodnar RJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):538-44. PubMed ID: 9808678
[TBL] [Abstract][Full Text] [Related]
54. Rational drug design of selective epsilon opioid receptor agonist TAN-821 and antagonist TAN-1014.
Fujii H; Nagase H
Curr Med Chem; 2006; 13(10):1109-18. PubMed ID: 16719773
[TBL] [Abstract][Full Text] [Related]
55. N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.
Coop A; Jacobson AE; Aceto MD; Harris LS; Traynor JR; Woods JH; Rice KC
Bioorg Med Chem Lett; 2000 Nov; 10(21):2449-51. PubMed ID: 11078198
[TBL] [Abstract][Full Text] [Related]
56. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
57. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.
Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
Bioorg Med Chem Lett; 2017 Aug; 27(16):3920-3924. PubMed ID: 28688957
[TBL] [Abstract][Full Text] [Related]
58. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of multimodal analgesic treatment of severe traumatic acute pain in mice pretreated with chronic high dose of buprenorphine inducing mechanical allodynia.
Coutens B; Derreumaux C; Labaste F; Minville V; Guiard BP; Moulédous L; Bounes V; Roussin A; Frances B
Eur J Pharmacol; 2020 May; 875():172884. PubMed ID: 31870829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
